Resistance to topoisomerase II poisons: is the answer in the promoter?
Kaufmann
S H
SH
Mayo Clinic and Department of Pharmacology, Mayo Medical School, Rochester, MN 55905, USA.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D004249:DNA Damage; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D011401:Promoter Regions, Genetic / Q000187:drug effects*; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D004250:DNA Topoisomerases, Type II